[go: up one dir, main page]

WO2007066189A3 - Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree - Google Patents

Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree Download PDF

Info

Publication number
WO2007066189A3
WO2007066189A3 PCT/IB2006/003416 IB2006003416W WO2007066189A3 WO 2007066189 A3 WO2007066189 A3 WO 2007066189A3 IB 2006003416 W IB2006003416 W IB 2006003416W WO 2007066189 A3 WO2007066189 A3 WO 2007066189A3
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
pyrrolo
prodrugs
dichloro
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/003416
Other languages
English (en)
Other versions
WO2007066189A2 (fr
Inventor
Tracy Lee Boyden
Feng Guo
Susan Deborah Lagreca
Douglas Alan Lorenz
Ravi Mysore Shanker
Franzanne Vreeland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2007066189A2 publication Critical patent/WO2007066189A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007066189A3 publication Critical patent/WO2007066189A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés représentés par la formule (I) ou leur sel pharmaceutiquement acceptable, leur promédicament ou leurs hydrates. L'invention concerne également des compositions pharmaceutiques contenant les composés représentés par la formule 1 et des méthodes de traitement de troubles hyperprolifératifs chez un mammifère consistant à administrer les composés représentés par la formule (I).
PCT/IB2006/003416 2005-12-09 2006-11-24 Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree Ceased WO2007066189A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09
US60/749,070 2005-12-09

Publications (2)

Publication Number Publication Date
WO2007066189A2 WO2007066189A2 (fr) 2007-06-14
WO2007066189A3 true WO2007066189A3 (fr) 2008-08-14

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003416 Ceased WO2007066189A2 (fr) 2005-12-09 2006-11-24 Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree

Country Status (8)

Country Link
AR (1) AR058293A1 (fr)
DO (1) DOP2006000271A (fr)
GT (1) GT200600496A (fr)
NL (1) NL2000337A1 (fr)
PE (1) PE20071037A1 (fr)
TW (1) TW200733965A (fr)
UY (1) UY29991A1 (fr)
WO (1) WO2007066189A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31406A1 (es) * 2007-10-19 2009-05-29 "producto de dispersion solida que contiene un compuesto a base de n-aril urea".
PA8800101A1 (es) * 2007-10-19 2009-05-15 Abbott Gmbh & Co Kg Producto de dispersion sólida que contiene un compuesto a base de n-aril urea
AU2009305669A1 (en) * 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
PH12012501337A1 (en) 2009-12-30 2012-12-17 Arqule Inc Substituted pyrrolo-aminopyrimidine compounds
WO2011163090A1 (fr) * 2010-06-23 2011-12-29 Metabolex, Inc. Compositions de 5-éthyl-2-{4-[4-(4-tétrazol-1-yl-phénoxyméthyl)-thiazol-2-yl]-pipéridin-1-yl}-pyrimidine
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
UA125503C2 (uk) 2012-06-13 2022-04-13 Інсайт Холдинґс Корпорейшн Заміщені трициклічні сполуки як інгібітори fgfr
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014172644A2 (fr) 2013-04-19 2014-10-23 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
UA121669C2 (uk) 2015-02-20 2020-07-10 Інсайт Корпорейшн Біциклічні гетероцикли як інгібітори fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
SI3788047T1 (sl) 2018-05-04 2024-11-29 Incyte Corporation Trdne oblike inhibitorja fgfr in postopki priprave le-teh
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4045151A1 (fr) 2019-10-14 2022-08-24 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (fr) 2019-12-04 2021-06-10 Incyte Corporation Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
EP4069695A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Dérivés d'un inhibiteur de fgfr
WO2021146424A1 (fr) 2020-01-15 2021-07-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
WO2022261160A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
CA3220155A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Heterocycles tricycliques utiles en tant qu'inhibiteurs de fgfr
JP2025015449A (ja) * 2023-07-18 2025-01-30 信越化学工業株式会社 固体分散体用組成物、固体分散体及び固体分散体の製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786A2 (fr) * 1997-08-11 1999-03-17 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786A2 (fr) * 1997-08-11 1999-03-17 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321772B2 (en) 2011-09-02 2016-04-26 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US9895373B2 (en) 2011-09-02 2018-02-20 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
US10131668B2 (en) 2012-09-26 2018-11-20 The Regents Of The University Of California Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1
US10822340B2 (en) 2012-09-26 2020-11-03 The Regents Of The University Of California Substituted imidazolopyrazine compounds and methods of using same
US11613544B2 (en) 2012-09-26 2023-03-28 The Regents Of The University Of California Substituted imidazo[1,5-a]pyrazines for modulation of IRE1

Also Published As

Publication number Publication date
WO2007066189A2 (fr) 2007-06-14
GT200600496A (es) 2007-07-17
TW200733965A (en) 2007-09-16
DOP2006000271A (es) 2007-08-15
AR058293A1 (es) 2008-01-30
NL2000337A1 (nl) 2007-06-12
PE20071037A1 (es) 2007-11-19
UY29991A1 (es) 2007-07-31

Similar Documents

Publication Publication Date Title
WO2007066189A3 (fr) Sels, promedicaments et formulations de 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-uree
CA2510853A1 (fr) Derives de pyrrolopyrimidine
WO2007138472A3 (fr) Dérivés de la triazolopyridazine
NO20085060L (no) Triazolpyrazinderivater anvendelige som anti-cancermidler
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
WO2003063864A3 (fr) Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
WO2004056786A3 (fr) Composes pour traiter le developpement anormal de cellules
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
WO2004020431A3 (fr) Nouveaux dérivées de benzoimidazole utilisés en tant qu'agents antiprolifératifs
TW200728307A (en) Novel spirochromanone derivatives
WO2003074529A3 (fr) Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
WO2005082892A3 (fr) Nouveaux composes de triazole en tant qu'agents antibacteriens et compositions pharmaceutiques en contenant
WO2007031933A3 (fr) Composition pharmaceutique stable a pyrimidine-sulfamide
WO2007056167A3 (fr) (quinazolinyl)phenyl-thiophenyl-sulfonylurees substituees et procedes pour les preparer
WO2008008660A3 (fr) Composés thérapeutiques
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
TW200626158A (en) Naphthaline derivatives
WO2007111983A8 (fr) Nouvelles combinaisons thérapeutiques pour le traitement ou la prévention de troubles psychotiques
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
WO2004111008A3 (fr) Utilisation d'un compose de formule i pour la preparation d'une composition pharmaceutique
WO2007146856A3 (fr) Gamma lactames substitués utilisés en tant qu'agents thérapeutiques
WO2006077024A3 (fr) Derives de 5-aminoindole
WO2005007642A3 (fr) Nouveaux amides utilises dans le traitement de la douleur
WO2004089943A8 (fr) Derives de [3.1.0] bicyclohexylphenyl-oxazolidinone antimicrobiens et leurs analogues

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06821007

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06821007

Country of ref document: EP

Kind code of ref document: A2